• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Decoupling of omicron variant infections and severe COVID-19.

作者信息

Madhi Shabir A, Ihekweazu Chikwe, Rees Helen, Pollard Andrew J

机构信息

South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Parktown 2193, South Africa.

World Health Organization, Hub for Pandemic and Epidemic Intelligence, Berlin, Germany.

出版信息

Lancet. 2022 Mar 12;399(10329):1047-1048. doi: 10.1016/S0140-6736(22)00109-X. Epub 2022 Feb 18.

DOI:10.1016/S0140-6736(22)00109-X
PMID:35189080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8856666/
Abstract
摘要

相似文献

1
Decoupling of omicron variant infections and severe COVID-19.奥密克戎变异株感染与重症新冠病毒肺炎的脱钩
Lancet. 2022 Mar 12;399(10329):1047-1048. doi: 10.1016/S0140-6736(22)00109-X. Epub 2022 Feb 18.
2
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
3
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.XBB.1.5 rS 疫苗在叙利亚仓鼠中针对 SARS-CoV-2 的 EG.5.1 变异株的免疫原性和疗效。
J Virol. 2024 Oct 22;98(10):e0052824. doi: 10.1128/jvi.00528-24. Epub 2024 Sep 4.
4
Durability of XBB.1.5 Vaccines against Omicron Subvariants.XBB.1.5疫苗对奥密克戎亚变体的有效性
N Engl J Med. 2024 Jun 13;390(22):2124-2127. doi: 10.1056/NEJMc2402779. Epub 2024 May 29.
5
Metabolic disorders, COVID-19 and vaccine-breakthrough infections.代谢紊乱、COVID-19 和疫苗突破性感染。
Nat Rev Endocrinol. 2022 Feb;18(2):75-76. doi: 10.1038/s41574-021-00608-9.
6
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
7
Audio Interview: The Omicron Variant of SARS-CoV-2.音频访谈：严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变种
N Engl J Med. 2021 Dec 2;385(23):e96. doi: 10.1056/NEJMe2118839.
8
Variant-adapted COVID-19 booster vaccines.变异株适应的 COVID-19 加强疫苗。
Science. 2023 Oct 13;382(6667):157-159. doi: 10.1126/science.adh2712. Epub 2023 Oct 12.
9
The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis.新冠病毒疫苗对儿童和青少年奥密克戎变异株的影响：一项系统评价和荟萃分析。
Front Public Health. 2024 Apr 10;12:1338208. doi: 10.3389/fpubh.2024.1338208. eCollection 2024.
10
A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.奥密克戎变异株体液和细胞免疫应答以及针对该变异株的疫苗效力的证据汇总表。
Immunol Lett. 2022 Mar;243:38-43. doi: 10.1016/j.imlet.2022.02.002. Epub 2022 Feb 4.

引用本文的文献

1
Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study.AZD1222（ChAdOx1 nCoV-19）的长期安全性和免疫原性：一项3期研究的2年随访
Vaccines (Basel). 2024 Aug 3;12(8):883. doi: 10.3390/vaccines12080883.
2
Sensitivity and specificity of COVID-19 screening by detection dogs: Results of the C19-Screendog multicenter study.通过检测犬进行新冠病毒筛查的敏感性和特异性：C19-Screendog多中心研究结果
Heliyon. 2023 Apr 25;9(5):e15640. doi: 10.1016/j.heliyon.2023.e15640. eCollection 2023 May.
3
Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis.预测疫苗对 COVID-19 重症的长期有效性和对变异株的有效性：一项荟萃分析。
Nat Commun. 2023 Mar 24;14(1):1633. doi: 10.1038/s41467-023-37176-7.
4
mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.mRNA 新冠疫苗加强针在澳大利亚具有高有效性和成本效益。
Vaccine. 2023 Apr 6;41(15):2439-2446. doi: 10.1016/j.vaccine.2023.01.075. Epub 2023 Feb 3.
5
Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi.在马拉维新冠疫苗接种率低、新冠病毒血清阳性率高的人群中，与重症相关的奥密克戎B.1.1.529变种感染并不常见。
EClinicalMedicine. 2023 Feb;56:101800. doi: 10.1016/j.eclinm.2022.101800. Epub 2022 Dec 30.
6
Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model.鼻腔冲洗可有效减轻叙利亚仓鼠模型中SARS-CoV-2奥密克戎毒株的感染、传播和肺部损伤。
iScience. 2022 Dec 22;25(12):105475. doi: 10.1016/j.isci.2022.105475. Epub 2022 Nov 2.
7
A Case Report of Breakthrough Infections With 2 SARS-CoV-2 Variants in a Lung Transplant Patient.肺移植患者 2 种 SARS-CoV-2 变异株突破性感染的病例报告。
Transplant Proc. 2022 Dec;54(10):2698-2701. doi: 10.1016/j.transproceed.2022.07.003. Epub 2022 Jul 26.
8
Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis.新型冠状病毒肺炎患者的抗凝治疗 - 一项更新的系统评价和荟萃分析。
Thromb Res. 2022 Nov;219:40-48. doi: 10.1016/j.thromres.2022.09.001. Epub 2022 Sep 8.
9
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia.用于分离和鉴定 SARS-CoV-2 变体的平台可快速鉴定澳大利亚的奥密克戎。
Nat Microbiol. 2022 Jun;7(6):896-908. doi: 10.1038/s41564-022-01135-7. Epub 2022 May 30.
10
Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?奥密克戎变异株能否提供针对 COVID-19 的自然免疫力？
Molecules. 2022 Mar 29;27(7):2221. doi: 10.3390/molecules27072221.

本文引用的文献

1
Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.安大略省针对 COVID-19 疫苗对有症状的 SARS-CoV-2 感染和关注变种的严重后果的有效性。
Nat Microbiol. 2022 Mar;7(3):379-385. doi: 10.1038/s41564-021-01053-0. Epub 2022 Feb 7.
2
COVID-19 vaccine strategies must focus on severe disease and global equity.新冠病毒疫苗策略必须聚焦于重症疾病和全球公平性。
Lancet. 2022 Jan 22;399(10322):406-410. doi: 10.1016/S0140-6736(21)02835-X. Epub 2021 Dec 16.
3
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?感染 SARS-CoV-2 或接种 SARS-CoV-2 疫苗是否会产生持久免疫力？
Lancet Respir Med. 2021 Dec;9(12):1450-1466. doi: 10.1016/S2213-2600(21)00407-0. Epub 2021 Oct 21.
4
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T1 response with a diverse TCR repertoire.AZD1222/ChAdOx1 nCoV-19 疫苗接种诱导具有多样化 TCR 谱的多功能 Spike 蛋白特异性 T1 反应。
Sci Transl Med. 2021 Nov 17;13(620):eabj7211. doi: 10.1126/scitranslmed.abj7211.
5
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.单突变对选定的 SARS-CoV-2 新兴变体刺突抗原性的贡献。
Virology. 2021 Nov;563:134-145. doi: 10.1016/j.virol.2021.09.001. Epub 2021 Sep 11.
6
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.恢复期患者血清和 BNT162b2 疫苗接种血清对 SARS-CoV-2 变异株的中和作用。
Nat Commun. 2021 Aug 26;12(1):5135. doi: 10.1038/s41467-021-25479-6.
7
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
8
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
9
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.